NASDAQ:SNGX

Soligenix (SNGX) Stock Forecast, Price & News

$0.54

0.00 (0.00%)

(As of 09/27/2023 ET)

Compare

Today's Range: $0.53
▼
$0.55
50-Day Range: $0.44
▼
$0.67
52-Week Range: $0.42
▼
$10.93

Volume: 31,952 shs
Average Volume: 367,793 shs
Market Capitalization: $4.35 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Soligenix MarketRank™ Forecast

Analyst Rating: 0.00 Rating Score
Upside/Downside: 460.0% Upside
$3.00 Price Target
Short Interest: Healthy
0.42% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.88
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.56) to ($1.74) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.36 out of 5 stars

2.0

Analyst's Opinion

Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Soligenix has a forecasted upside of 460.0% from its current price of $0.54.
Amount of Analyst Coverage
Soligenix has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.42% of the float of Soligenix has been sold short.
Short Interest Ratio / Days to Cover
Soligenix has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Soligenix has recently increased by 63.86%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Soligenix does not currently pay a dividend.
Dividend Growth
Soligenix does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SNGX.

3.3

News and Social Media Coverage

News Sentiment
Soligenix has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Soligenix this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for SNGX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
MarketBeat Follows
3 people have added Soligenix to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Soligenix insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.36% of the stock of Soligenix is held by insiders.
Percentage Held by Institutions
Only 17.80% of the stock of Soligenix is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Soligenix are expected to decrease in the coming year, from ($1.56) to ($1.74) per share.

See Top Rated MarketRank™ Stocks Here

About Soligenix (NASDAQ:SNGX) Stock

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

SNGX Price History

30 days | 90 days | 365 days | Advanced Chart

SNGX Stock News Headlines

September 25, 2023 | finance.yahoo.com

Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures

September 22, 2023 | prnewswire.com

Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders

September 28, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

August 24, 2023 | finance.yahoo.com

SNGX: HyBryte™ Expanded Treatment Trial Underway

August 21, 2023 | finanznachrichten.de

Soligenix, Inc.: Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results

August 21, 2023 | msn.com

Soligenix GAAP EPS of -$0.22 beats by $0.16, revenue of $0.2M in-line

August 21, 2023 | finance.yahoo.com

Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results

August 2, 2023 | finance.yahoo.com

SNGX - Soligenix, Inc.

September 28, 2023 | Chaikin Analytics (Ad)

Holding NVDA? Read This Now

NVDA is likely not the best buy for A.I. investors. 50-year Wall Street veteran Marc Chaikin reveals what to buy instead. Learn more here.

July 19, 2023 | finance.yahoo.com

SNGX: Expanding SGX302 Phase 2a Study in Psoriasis…

June 29, 2023 | finance.yahoo.com

Soligenix, Inc. CEO is Featured in an Interview with SmallCaps Daily

June 2, 2023 | finanznachrichten.de

Soligenix, and Graphex Group Interviews to Air on Bloomberg TV on the RedChip Money Report

June 2, 2023 | finance.yahoo.com

Soligenix, and Graphex Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R)

May 30, 2023 | finance.yahoo.com

SNGX: Positive Results for Compatibility Study of HyBryte in CTCL

May 16, 2023 | finanznachrichten.de

Soligenix, Inc.: Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results

May 16, 2023 | finance.yahoo.com

Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis

May 15, 2023 | finance.yahoo.com

Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results

May 11, 2023 | finance.yahoo.com

Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma

May 9, 2023 | finance.yahoo.com

Soligenix Announces Closing of $8.5 Million Public Offering

May 5, 2023 | finance.yahoo.com

Soligenix Announces Pricing of $8.5 Million Public Offering

May 4, 2023 | finance.yahoo.com

Why Are Soligenix Shares Trading Higher Today

May 3, 2023 | finance.yahoo.com

Soligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors

May 1, 2023 | finance.yahoo.com

Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease

April 24, 2023 | finance.yahoo.com

SNGX: Planning for Second Phase 3 Study for HyBryte™ in CTCL…

April 24, 2023 | finance.yahoo.com

Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma

April 14, 2023 | msn.com

Soligenix Shares Tumble as FDA Demands More Data

April 14, 2023 | msn.com

Soligenix stock sinks as FDA seeks additional positive results for cancer drug

See More Headlines

Receive SNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter.

SNGX Company Calendar

Last Earnings: 8/21/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SNGX
CUSIP: N/A
CIK: 812796
Web: www.soligenix.com
Phone: (609) 538-8200
Fax: 609-452-6467
Employees: 13
Year Founded: 1987

Price Target and Rating

Average Stock Price Forecast: $3.00
High Stock Price Forecast: $3.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +460.0%
Consensus Rating
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-13,800,000.00
Net Margins: -943.00%
Pretax Margin: -1,056.62%
Return on Equity: -3,826.28%
Return on Assets: -65.21%

Debt

Debt-to-Equity Ratio: 0.36
Current Ratio: 2.34
Quick Ratio: 2.34

Sales & Book Value

Annual Sales: $950,000.00
Price / Sales: 4.58
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.85) per share
Price / Book: -0.63

Miscellaneous

Outstanding Shares: 8,120,000
Free Float: 8,006,000
Market Cap: $4.35 million
Optionable: Not Optionable
Beta: 1.67

Social Links

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Christopher J. Schaber Ph.D. (Age 57)
Chairman of Directors, CEO & Pres
Comp: $638.13k

Mr. Jonathan L. Guarino CPA (Age 50)
CGMA, Sr. VP, CFO & Corp. Sec.
Comp: $304.31k

Dr. Oreola Donini Ph.D. (Age 51)
Sr. VP & Chief Scientific Officer
Comp: $336.98k

Dr. Richard C. Straube M.D. (Age 71)
MSc., Sr. VP & Chief Medical Officer
Comp: $215.07k

Key Competitors

View All Competitors

Institutional Ownership

Anson Funds Management LP
Bought 514,144 shares on 8/14/2023
Ownership: 6.332%

View All Institutional Transactions

SNGX Stock - Frequently Asked Questions

What is Soligenix's stock price forecast for 2023?: 0 equities research analysts have issued 12-month price objectives for Soligenix's stock. Their SNGX share price forecasts range from $3.00 to $3.00. On average, they anticipate the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 460.0% from the stock's current price.
View analysts price targets for SNGX or view top-rated stocks among Wall Street analysts.
How have SNGX shares performed in 2023?: Soligenix's stock was trading at $0.4520 at the beginning of 2023. Since then, SNGX stock has increased by 18.5% and is now trading at $0.5357.
View the best growth stocks for 2023 here.
Are investors shorting Soligenix?: Soligenix saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 40,800 shares, an increase of 63.9% from the August 31st total of 24,900 shares. Based on an average daily volume of 140,900 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.4% of the company's shares are sold short.
View Soligenix's Short Interest.
When is Soligenix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our SNGX earnings forecast.
How were Soligenix's earnings last quarter?: Soligenix, Inc. (NASDAQ:SNGX) released its quarterly earnings data on Monday, August, 21st. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.32. The biopharmaceutical company had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.20 million. Soligenix had a negative trailing twelve-month return on equity of 3,826.28% and a negative net margin of 943.00%.
What other stocks do shareholders of Soligenix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Trevena (TRVN), Vaxart (VXRT), OPKO Health (OPK), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Actinium Pharmaceuticals (ATNM).

What is Soligenix's stock symbol?: Soligenix trades on the NASDAQ under the ticker symbol "SNGX."
Who are Soligenix's major shareholders?: Soligenix's stock is owned by many different institutional and retail investors. Top institutional shareholders include Anson Funds Management LP (6.33%). Insiders that own company stock include Christopher J Schaber, Jerome B Zeldis, Jonathan L Guarino and Richard Straube.
View institutional ownership trends.
How do I buy shares of Soligenix?: Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Soligenix's stock price today?: One share of SNGX stock can currently be purchased for approximately $0.54.
How much money does Soligenix make?: Soligenix (NASDAQ:SNGX) has a market capitalization of $4.35 million and generates $950,000.00 in revenue each year.
How can I contact Soligenix?: Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The official website for the company is www.soligenix.com. The biopharmaceutical company can be reached via phone at (609) 538-8200, via email at ir@soligenix.com, or via fax at 609-452-6467.

This page (NASDAQ:SNGX) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial